MENU
+Compare
PHAR
Stock ticker: NASDAQ
AS OF
Aug 15 closing price
Price
$11.65
Change
+$0.27 (+2.37%)
Capitalization
778.38M

PHAR Pharming Group NV Forecast, Technical & Fundamental Analysis

Pharming Group is a biopharmaceutical company focused in transforming the lives of patients with rare, debilitating, and life-threatening diseases... Show more

PHAR
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Interact to see
Advertisement
A.I.Advisor
a Summary for PHAR with price predictions
Aug 15, 2025

PHAR's Indicator enters downward trend

The Aroon Indicator for PHAR entered a downward trend on August 01, 2025. Tickeron's A.I.dvisor identified a pattern where the AroonDown red line was above 70 while the AroonUp green line was below 30 for three straight days. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options. A.I.dvisor looked at 180 similar instances where the Aroon Indicator formed such a pattern. In of the 180 cases the stock moved lower. This puts the odds of a downward move at .

Price Prediction Chart

Technical Analysis (Indicators)

Bearish Trend Analysis

The 10-day RSI Indicator for PHAR moved out of overbought territory on August 11, 2025. This could be a bearish sign for the stock. Traders may want to consider selling the stock or buying put options. Tickeron's A.I.dvisor looked at 17 similar instances where the indicator moved out of overbought territory. In of the 17 cases, the stock moved lower in the following days. This puts the odds of a move lower at .

The Moving Average Convergence Divergence Histogram (MACD) for PHAR turned negative on August 15, 2025. This could be a sign that the stock is set to turn lower in the coming weeks. Traders may want to sell the stock or buy put options. Tickeron's A.I.dvisor looked at 60 similar instances when the indicator turned negative. In of the 60 cases the stock turned lower in the days that followed. This puts the odds of success at .

Following a 3-day decline, the stock is projected to fall further. Considering past instances where PHAR declined for three days, the price rose further in of 62 cases within the following month. The odds of a continued downward trend are .

PHAR broke above its upper Bollinger Band on July 31, 2025. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.

Bullish Trend Analysis

The Stochastic Oscillator demonstrated that the ticker has stayed in the oversold zone for 2 days, which means it's wise to expect a price bounce in the near future.

The Momentum Indicator moved above the 0 level on July 31, 2025. You may want to consider a long position or call options on PHAR as a result. In of 106 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are .

PHAR moved above its 50-day moving average on July 31, 2025 date and that indicates a change from a downward trend to an upward trend.

The 10-day moving average for PHAR crossed bullishly above the 50-day moving average on August 06, 2025. This indicates that the trend has shifted higher and could be considered a buy signal. In of 15 past instances when the 10-day crossed above the 50-day, the stock continued to move higher over the following month. The odds of a continued upward trend are .

Following a 3-day Advance, the price is estimated to grow further. Considering data from situations where PHAR advanced for three days, in of 183 cases, the price rose further within the following month. The odds of a continued upward trend are .

Fundamental Analysis (Ratings)

The Tickeron PE Growth Rating for this company is (best 1 - 100 worst), pointing to outstanding earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.

The Tickeron Price Growth Rating for this company is (best 1 - 100 worst), indicating steady price growth. PHAR’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.

The Tickeron Valuation Rating of (best 1 - 100 worst) indicates that the company is slightly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (3.332) is normal, around the industry mean (19.528). P/E Ratio (0.000) is within average values for comparable stocks, (52.377). PHAR's Projected Growth (PEG Ratio) (0.000) is slightly lower than the industry average of (2.945). Dividend Yield (0.000) settles around the average of (0.042) among similar stocks. P/S Ratio (2.622) is also within normal values, averaging (294.394).

The Tickeron SMR rating for this company is (best 1 - 100 worst), indicating slightly better than average sales and a considerably profitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.

The Tickeron Profit vs. Risk Rating rating for this company is (best 1 - 100 worst), indicating that the returns do not compensate for the risks. PHAR’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 95, placing this stock worse than average.

View a ticker or compare two or three
PHAR
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Interact to see
Advertisement
A.I. Advisor
published Earnings

PHAR is expected to report earnings to fall 308.33% to -12 cents per share on November 06

Pharming Group NV PHAR Stock Earnings Reports
Q3'25
Est.
$-0.12
Q2'25
Beat
by $0.07
Q1'25
Missed
by $0.21
Q4'24
Beat
by $0.07
Q3'24
Missed
by $0.02
The last earnings report on July 31 showed earnings per share of 5 cents, beating the estimate of -1 cents. With 3.00K shares outstanding, the current market capitalization sits at 778.38M.
A.I. Advisor
published General Information

General Information

Industry Biotechnology

Profile
Fundamentals
Details
Industry
N/A
Address
Darwinweg 24
Phone
+31 715247400
Employees
332
Web
https://www.pharming.com
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
MFs / NAMEPrice $Chg $Chg %
RYECX184.08N/A
N/A
Rydex Energy C
CSSCX20.36N/A
N/A
Columbia Small Cap Value I C
SCVAX35.57N/A
N/A
Allspring Small Company Value A
NWKEX30.13N/A
N/A
Nationwide WCM Focused Sm Cp R6
NYVTX26.83-0.21
-0.78%
Davis NY Venture A

PHAR and Stocks

Correlation & Price change

A.I.dvisor tells us that PHAR and APLM have been poorly correlated (+31% of the time) for the last year. This A.I.-generated data suggests there is low statistical probability that PHAR and APLM's prices will move in lockstep.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To PHAR
1D Price
Change %
PHAR100%
+1.16%
APLM - PHAR
31%
Poorly correlated
+1.90%
ANTX - PHAR
29%
Poorly correlated
+0.48%
ADPT - PHAR
27%
Poorly correlated
-0.62%
IBRX - PHAR
27%
Poorly correlated
-3.90%
ATXS - PHAR
26%
Poorly correlated
-1.60%
More